| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Riviciclib HCl (P276-00) is a flavonoid analog which acts as a novel inhibitor of CDK1 (cyclin-dependent kinase), CDK4 and CDK9 with IC50 of 79 nM, 63 nM and 20 nM, respectively. P276-00 has the capacity to stop transcription of cells in the G1/S phase. In experiments using NSCLC cell lines, P276-00 demonstrated a strong ability to suppress cell proliferation, which in turn reduced the potential for colony formation by obstructing the cell cycle. By reducing the expression of CCND1, P276-00 treatment for 12 hours could significantly inhibit the ability of head and neck squamous carcinoma cell lines (FaDu, Detroits-562, SCC-25) to proliferate. The IC50 value for these cell lines varied between 0.8 and 1.7 uM.
| Targets |
CDK9- Cyclin T1 (IC50 = 0.020 μM); cdk4-cyclin D1 (IC50 = 0.063 μM); CDK1-Cyclin B (IC50 = 0.079 μM); cdk2-cyclin A (IC50 = 0.224 μM); cdk2-cyclin E (IC50 = 2.500 μM); cdk6-cyclin D3 (IC50 = 0.396 μM); CDK9-cyclin H (IC50 = 2.900 μM)
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
The Cdk4-D1/Cdk2-E enzyme assay is conducted using Millipore Multiscreen filtration plates in a 96-well format. A single filter plate is used for each step of the assay. After prewetting the filtration wells with 100 μL of kinase buffer (which contains 50 mmol/L HEPES (pH of 7.5), 10 mmol/L MgCl2, and 1 mmol/L EGTA), the solution is vacuum-withdrawn. Vacuum is applied to the filter plate while it is on the vacuum manifold. Each well receives 50 μL of GST-Rb bound to GSH-Sepharose beads in kinase buffer (0.5 μg GST-Rb/50 μL). A reaction mix containing ATP (cold + hot) and 4× phosphatase inhibitor mix (40 μmol/L unlabeled ATP, 10 μCi/mL γ32P-ATP, 40 mmol/L h-glycerophosphate, 4 mmol/L DTT, 0.4 mmol/L NaF, 0.4 mmol/L sodium orthovanadate) diluted in kinase buffer is added to each well in approximately 25 μL. An additional 25 μL volume is then added containing either the test compound (4×final concentration in kinase buffer) or kinase buffer alone (control). To start the reaction, add 50 μL (100 ng) of human Cdk4-D1/Cdk2-E enzyme in kinase buffer to each well. The reaction is then allowed to run at 30°C for 30 minutes. The filter plate is air-dried and put in a Multiscreen adapter plate after the reaction is finished and vacuum is applied once more. The plate is then cleaned three times using the TNEN buffer, which is composed of 20 mmol/L Tris (pH, 8.0), 100 mmol/L NaCl, 1 mmol/L EDTA, and 0.5% nonidet-P40. The plate is covered with a Top-Seal A film after adding 30 μL of Packard Microscint-O cocktail. With a Top Count scintillation counter, 32P-GST-Rb is quantified in 96-well filter plates. The initial concentration of each compound tested is 1 μmol/L. More profiling is done on compounds exhibiting 50% or more inhibition in order to determine their IC50.
|
|
| Cell Assay |
In a 96-well plate, the cells are seeded at a density of 3,000–5,000 per well, depending on the type of cell, in 180 μL of culture medium. The cells are then allowed to adhere over night in the incubator. Compounds in varying concentrations are added to the wells, and they are then incubated at 37°C for 48 hours. Each well receives an addition of 3H-thymidine (0.25 μCi), and the radiolabel is allowed to be incorporated for a duration of 5 to 7 hours. After the incubation period, cells are harvested onto GF/B unifilter plates using a Packard Filtermate Universal harvester, and the 96-well liquid scintillation counter Packard Top Count is used to count the plates.
|
|
| Animal Protocol |
H-460 xenograft
50 mg/kg once daily or 30 mg/kg twice daily i.p. |
|
| References |
| Molecular Formula |
C21H21CL2NO5
|
|---|---|
| Molecular Weight |
438.301
|
| Exact Mass |
401.103
|
| Elemental Analysis |
C, 57.55; H, 4.83; Cl, 16.18; N, 3.20; O, 18.25
|
| CAS # |
920113-03-7
|
| Related CAS # |
Riviciclib;920113-02-6
|
| Appearance |
Solid powder
|
| SMILES |
CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
|
| InChi Key |
OOVTUOCTLAERQD-OJMBIDBESA-N
|
| InChi Code |
InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1
|
| Chemical Name |
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride
|
| Synonyms |
P-27600; P 27600; P27600; P276-00; P-276-00; P 276-00; Riviciclib HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50~88 mg/mL (114.1~200.8 mM)
Ethanol: ~7 mg/mL (~16 mM) Water: ~88 mg/mL (~200.8 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2815 mL | 11.4077 mL | 22.8154 mL | |
| 5 mM | 0.4563 mL | 2.2815 mL | 4.5631 mL | |
| 10 mM | 0.2282 mL | 1.1408 mL | 2.2815 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
